Adjuvante Therapie des Nierenzellkarzinoms

Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma

CONTEXT

Systemic treatment of metastatic renal cell carcinoma (mRCC) with targeted therapies became widely accepted; however, there are few patients who greatly benefit from immunochemotherapy (ICT). It is crucial to recognize these patients for individual treatment.

OBJECTIVES

Definition of protein patterns in tissue and serum from mRCC-patients to predict benefit from ICT.

MATERIALS AND METHODS

Twenty-five tissue samples and 59 sera were analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Protein peaks of interest were identified by 2D-PAGE and peptide mass fingerprinting. Validation was carried out by Western Blot and ELISA.

RESULTS

Protein patterns associated with therapy response were determined. Caveolin-1 (CAV-1) and plasminogen activator inhibitor 1 (PAI-1) were identified in tissue; serum amyloid A (SAA) and transthyretin (TTR) were found in serum.

CONCLUSION

Individual prediction of therapy benefit and selecting patients for ICT based on molecular biological profiles appear to be feasible in the future.

Komplette Remission beim pulmonal metastasierten Nierenzellkarzinom durch Inhalationstherapie mit Interleukin-2 nach erfolgloser systemischer Immunchemotherapie

Therapy of metastasized renal cell carcinoma is based on systemic immunotherapeutic strategies, if surgical resection is not possible. The costs of inhalative Interleukin-2 therapy in case of pulmonary metastases as off-label-use are not accepted by compulsory health insurance yet.We report on a female patient with pulmonary metastasized renal cell carcinoma who had tumor progression after immunochemotherapy that followed complete response after inhalative therapy with Interleukin-2.